Oxaliplatin
- PDF / 169,773 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 59 Downloads / 125 Views
1 S
Allergic reaction: case report A man in his 80s’ developed an allergic reaction during treatment with oxaliplatin for transverse colon cancer. The man, who was diagnosed with (stage IIa, pt3pN0cM0) transverse colon cancer had undergone transverse colectomy. Nineteen months after the surgery, chest abdominal contrast CT showed disseminated nodules in his abdominal cavity indicative of intraperitoneal dissemination relapse. Hence, he started receiving mFOLFOX6 chemotherapy with bevacizumab. His standard treatment regimen included oxaliplatin 85 mg/m2 every 2 weeks [route not stated], along with fluorouracil [5-Fluorouracil], folinic acid [leucovorin] and bevacizumab. However, in view of his elderly age, his chemotherapy dose was decreased to 80% of the standard dose. He had received 8 courses of chemotherapy. During the eighth course of chemotherapy, he developed a grade III allergic reaction, which was attributed to oxaliplatin [time to reaction onset not stated]. Therefore, the man’s chemotherapy was switched to sLV5FU2 (fluorouracil and folinic acid) chemotherapy along with bevacizumab. Treatment with oxaliplatin excluded. After 2 courses of sLV5FU2 plus bevacizumab chemotherapy, a significant decrease in disseminated nodules was observed. After 7 courses of sLV5FU2 plus bevacizumab chemotherapy, no disseminated nodules regrowth was noted [outcome of reaction not stated]. Takahashi S, et al. Transverse Colon Cancer with Peritoneal Metastasis Successfully Treated with mFOLFOX6 plus Bevacizumab-A Case Report. Gan to Kagaku Ryoho 47: 803498460 1125-1127, No. 7, Jul 2020. Available from: URL: http://www.pieronline.jp/content/issue/0385-0684/47070 [Japanese; summarised from a translation]
0114-9954/20/1819-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved
Reactions 29 Aug 2020 No. 1819
Data Loading...
